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ABSTRACT  
 
Introduction: Knowledge about the biological, clinical and pathological 
characteristics of invasive lobular carcinoma of breast has remained complex 
and unclear due to rarity of such cases.   
Objectives: This is a retrospective study to highlight the 
clincopathological features of invasive lobular carcinoma; and to identify the 
incidence rate among the invasive breast cancers. 
Methods: Clinical and histological data from archived and reported 508 
cases diagnosed as invasive breast cancers, from period 2005 – 2009 at 
National Health Laboratory were collected and reviewed. Among 508 cases, 
30 patients reported as invasive lobular carcinoma of the breast were studied 
by recutting new section and histopathologically assessed and 
immunohistochemical reactivity for ER and PR done on paraffin embedded 
blocks of the 30 cases of ILC.  
Results: The incidence rate of invasive lobular carcinoma was 5.9%. 
The average age of the patients was 57.5 years (range, 30- 85 years), and 60% 
(18) were in postmenopausal age. Most of the tumours were classical ILC 
grade 2 in 73.3% of cases. The other lymph nodes were positive in 40% and 
negative in 60% with ILC. The proportion of estrogen and progesterone 
receptors positive tumours were 21(70%) cases and 15(50%) cases 
respectively. 
Conclusions: The incidence rate of ILC was increasing as well as other 
invasive breast carcinomas. ILC is more likely to occur in older age. The 
lymph node metastasis tends to be lower in ILC than in other invasive breast 
carcinomas. The ER and PR reactivity is more frequently positive with ILC. 
  
  ﺍﻟﻤﺴﺘﺨﻠﺹ
  
ﻟﻭﺠﻴﺔ ﻭﺍﻟﺴﺭﻴﺭﻴﺔ ﻭﺍﻟﻤﺭﻀﻴﺔ ﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻟﻠﺜﺩﻱ ﻭﺨﺼﺎﺌﺹ ﺍﻟﺒﻴﺍﻟﻤﻌﺭﻓﺔ : ﻤﻘﺩﻤﺔ
  .ﺏ ﻟﻨﺩﺭﺓ ﻤﺜل ﻫﺫﻩ ﺍﻟﺤﺎﻻﺕﻻﺘﺯﺍل ﻤﻌﻘﺩﺓ ﻭﻏﻴﺭ ﻭﺍﻀﺤﺔ ﻭﻗﺩ ﻴﺭﺠﻊ ﺍﻟﺴﺒ
ﻫﺫﻩ ﺩﺭﺍﺴﺔ ﺍﺴﺘﻘﺼﺎﺌﻴﺔ ﺍﻟﻰ ﺍﻟﻭﺭﺍﺀ ﺘﻬﺩﻑ ﺍﻟﻲ ﺘﺴﻠﻴﻁ ﺍﻟﻀﻭﺀ ﻋﻠﻲ ﺒﻌﺽ ﺍﻟﺨﺼﺎﺌﺹ  :ﺍﻻﻫﺩﺍﻑ
ﺍﻟﺴﺭﻴﺭﻴﺔ ﻭﺍﻟﻤﺭﻀﻴﺔ ﻭﺒﺎﻻﻀﺎﻓﺔ ﺍﻟﻲ ﻤﻌﺭﻓﺔ ﻤﻌﺩل ﺤﺩﻭﺙ ﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻤﻥ ﺒﻴﻥ ﺍﻨﻭﺍﻉ 
  .ﻟﻨﺴﻴﺠﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻤﻥ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯﺍ
ﺒﺎﻟﻤﻌﻤل ﺍﻟﻘﻭﻤﻲ ﺍﻟﺼﺤﻲ ﻓﻲ   ﻤﻥ ﺴﺠﻼﺕ ﺍﻟﻤﺭﻀﻰﺤﺎﻟﺔ  805ﺘﻡ ﺠﻤﻊ ﺒﻴﺎﻨﺎﺕ : ﻤﻨﻬﺠﻴﺔ ﺍﻟﺒﺤﺙ
 ﺍﻭﺭﺍﻡ ﺜﺩﻯﻡ  ﻭﺍﻟﺘﻰ ﺸﺨﺼﺕ ﺒﻌﺩ ﺍﻟﻔﺤﺹ ﺍﻟﺴﺭﻴﺭﻱ ﻭﺍﻟﻨﺴﻴﺠﻰ ﺒﺎﻨﻬﺎ 9002 – 5002ﺍﻟﻔﺘﺭﺓ ﻤﻥ 
، ﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻟﻠﺜﺩﻱﺒﺎﺨﺎﺼﺔ ﺤﺎﻟﺔ  03ﺘﻤﺕ ﺩﺭﺍﺴﺔ  ﻤﻥ ﺒﻴﻥ ﻫﺫﻩ ﺍﻟﺤﺎﻻﺕ. ﺴﺭﻁﺎﻨﻴﺔ
ﺴﻴﺠﻲ ﻭﺇﺠﺭﺍﺀ ﺍﻟﻔﺤﺹ ﺍﻟﻤﻨﺎﻋﻲ ﻭﺫﻟﻙ ﺒﻌﺩ ﺘﺤﻀﻴﺭ ﺸﺭﺍﺌﺢ ﻭﻤﺭﺍﺠﻌﺘﻬﺎ ﻭﺍﻟﺘﺄﻜﺩ ﻤﻥ ﺍﻟﺘﺸﺨﻴﺹ ﺍﻟﻨ
  .ﺍﻟﻨﺴﻴﺠﻲ ﺍﻟﻜﻴﻤﻴﺎﺌﻲ ﻟﻤﺴﺘﻘﺒﻼﺕ ﻫﺭﻤﻭﻥ ﺍﻹﺴﺘﺭﻭﺠﻴﻥ ﻭﺍﻟﺒﺭﺠﺴﺘﺭﻭﻥ ﻟﻬﺎ
ﻤﺘﻭﺴﻁ   ﻭﻤﻌﺩل %9,5ﻤﻌﺩل ﺤﺩﻭﺙ ﺍﻻﺼﺎﺒﺔ ﺒﺎﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ  :ﺍﻟﻨﺘﺎﺌﺞ
ﻭﺘﻌﺘﺒﺭ ﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﺍﻻﻜﺜﺭﺤﺩﻭﺜﺎ  ﻋﻨﺩ ( ﺴﻨﺔ 58 – 03ﺘﺘﺭﺍﻭﺡ ﺒﻴﻥ % )755.ﺍﻻﻋﻤﺎﺭ
ﺃﺸﺎﺭﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻰ ﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﺔ ﻓﻰ ﺍﻻﻨﺴﺠﺔ ﻓﻰ ﺍﻟﺴﺭﻁﺎﻨﺔ  .ﺩ ﺴﻥ ﺍﻻﻨﺠﺎﺏ ﺍﻟﻨﺴﺎﺀ ﻤﺎ ﺒﻌ
ﺍﻨﺘﺸﺎﺭﺍﻟﺴﺭﻁﺎﻨﺔ  ،%3.37 ﻭﺒﻨﺴﺒﺔ 2ﻋﻨﺩ ﺩﺭﺠﺔ  ﺍﻟﻭﺭﻡ ﺍﻟﻨﺴﻴﺠﻰﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻭ ﻜﺎﻨﺕ ﺍﻏﻠﺒﻬﺎ 
ﻭ . ﻤﻥ ﺍﻟﺤﺎﻻﺕ %06 ﻓﻲ ﻭﺴﻠﺒﻴﺔ% 04ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﻓﻰ ﺍﻟﻐﺩﺩ ﺍﻟﻠﻴﻤﻘﺎﻭﻴﺔ ﻜﺎﻨﺕ ﺍﻴﺠﺎﺒﻴﺔ ﻓﻲ 
  .ﻋﻠﻲ ﺍﻟﺘﻭﺍﻟﻰ% 05ﻭ% 07   (ﻭﺠﺴﺘﺭﻭﻥﺍﺴﺘﺭﻭﺠﻴﻥ ﺒﺭ)ﻟﻤﻘﺒﻼﺕ ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﻨﺴﺒﺔ ﺍﻻﺴﺘﺠﺎﺒﺔ 
ﺩﻴﺎﺩ ﻨﺴﺒﺔ ﺍﻻﻨﻭﺍﻉ ﺍﻟﻨﺴﻴﺠﻴﺔ ﻊ ﺇﺯﻤﻤﻌﺩل ﺍﻻﺼﺎﺒﺔ ﺒﺎﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﺘﺫﺩﺍﺩ  :ﺍﻟﺘﻀﻤﻴﻥ
 .ﺃﻜﺜﺭ ﺤﺩﻭﺜﺎ ﻓﻲ ﺍﻻﻋﻤﺎﺭ ﺍﻟﻤﺘﻘﺩﻤﺔﺍﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻔﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ . ﺍﻟﻐﺎﺯﻴﺔ ﺍﻻﺨﺭﻯ ﻤﻥ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯ
 ﺎﺕﻐﺩﺩ ﺍﻟﻠﻴﻤﻔﺎﻭﻴﺔ ﺒﻨﺴﺏ ﺍﻗل ﻤﻥ ﺍﻨﻭﺍﻉ ﺍﻟﻨﺴﻴﺠﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ ﺍﻻﺨﺭﻱ ﻤﻥ ﺴﺭﻁﺎﻨﻭﺍﻨﺘﺸﺎﺭﻩ ﻤﻥ ﺨﻼل ﺍﻟ
ﻤﺴﺘﻘﺒﻼﺕ ﻫﺭﻤﻭﻨﻲ ﺍﻹﺴﺘﺭﻭﺠﻴﻥ ﻭﺍﻟﺒﺭﻭﺠﺴﺘﺭﻭﻥ ﻓﻲ ﺍﻟﻐﺎﻟﺏ ﺘﻭﺠﺩ ﻤﻭﺠﺒﻪ ﻋﻨﺩ ﻤﺭﻀﻰ . ﺍﻟﺜﺩﻯ
  .ﺍﻟﺴﺭﻁﺎﻨﺔ ﺍﻟﻘﺼﺼﻴﺔ ﺍﻟﻐﺎﺯﻴﺔ
 
 
 
LIST OF ABBREVIATIONS 
 
DCIS          Ductal Carcinoma In-Situ 
EIC             Extensive Intraductal Component 
ER              Estrogen Receptor 
GCDPF      Gross Cystic Disease fluid protein 
IDC              Invasive Ductal Carcinoma 
ILC               Invasive Lobular Carcinoma                  
LCIS            Lobular Carcinoma In- Situ 
NOS            Not Otherwise Specified 
NR                Not Recommended 
PR              Progesterone Receptor 
R               Recommended 
SEER          Surveillance Epidemiology and End Results 
TDLU          Terminal Duct-Lobular Unit 
 
 
 
 
 
 
 
  
 
1. INTRODUCTION AND LITERATURE REVIEW 
 
Knowledge about the biological, clinical and pathological characteristics of 
invasive lobular breast carcinoma of the breast is complex and unclear. 
Invasive lobular carcinoma of the breast (ILC) comprises approximately              
5- 10% of all invasive breast cancer.(6) A precise histological and clinical 
delineation of invasive lobular carcinoma, including its variants form, has been 
elusive.(11)  
Invasive lobular breast carcinoma (ILC) displays diverse histological pattern 
varying from classical variant through solid to pleomorphic subtypes.(4)  
These tumours are characterized microscopically by small cells that insidiously 
infiltrate the mammary stroma and adipose tissue individually and in single file 
pattern, often forming target –like configuration around normal breast ducts, 
frequently inducing only minimal fibrous reaction.(3) 
 By virtue of their distinctive growth pattern and biology, lobular carcinomas 
often fail to form distinct masses that can easily be diagnosed by palpation or 
mammography. This can make early diagnosis challenging and breast 
conservation approaches more difficult.(6) 
 Lobular carcinomas may have a substantially increased propensity for 
multifocal and mutlicentric distribution and bilaterality. Invasive lobular 
  
 
carcinoma frequently metastasized to unusual sites, including the 
gastrointestinal tract, peritoneum, and adnexa.(6, 16)  
The majority of invasive lobular breast carcinomas (ILC) show strong 
expression of estrogen and progesterone receptors, a higher rate than other 
invasive carcinomas.(4)  
Previously invasive lobular carcinoma (ILC) was considered to be an 
aggressive tumour, but later on it was shown to have fairly favorable 
prognosis. However, some histological subtypes (i.e pleomorphic) have much 
worse prognosis.(16) 
1.1. Anatomy and pathology of the breast: 
The breast or mammary gland is covered by skin and subcutaneous tissue and 
rests on the pecteralis muscle, from which it is separated by a fascia. The 
morpho-functional unit of the organ is single gland, a complex branching 
structure that is composed of two major parts: the terminal duct-lobular unit 
(TDLU) and the large duct system.(1) 
The breast is composed of glandular ducts and lobules, connective tissue and 
fat.  The ductal-lobular unit (TDLU) is the basic structural unit of the breast 
and is lined by epithelial cells. Specifically, most breast cancer is thought to 
originate in the terminal ductal lobular unit (TDLU) epithelial cells.(5) Breast 
also contains blood and lymphatic vessels. Most lymphatic vessels within the 
  
 
breast lead to the axillary lymph nodes, some also connect to supra-or 
infraclavicular, and internal mammary nodes.(1, 14)  
1.2. Invasive breast carcinomas: 
More than 95% of breast malignancies arise from the breast epithelial elements 
and therefore they are carcinomas. The term "breast Carcinoma" encompasses 
a diverse group of lesions which differ in microscopic appearance and biologic 
behavior. Invasive mammary carcinomas are broadly classified into no special 
type (ductal) and special type cancer. Invasive lobular carcinoma is a member 
of latter category representing 5 – 10% of all invasive cancers.(3, 6) 
Breast carcinomas can be divided into two major groups: 
1- In situ carcinoma: The tumor cells remain confined to the duct or 
lobules and shows no evidence of light microscopic invasion into surrounding 
stroma. 
2- Invasive carcinomas: The tumor cells invade the breast stroma' and 
have the potential to metastasize and result in death of patient. 
The invasive breast carcinomas consist of several histological subtypes; the 
estimated percentages are from a contemporary population- based of series of 
135,157 women with breast cancer reported to the Surveillance Epidemiology 
and End Results (SEER) database of the National Cancer Institute between 
1992 and 2001 (Seattle, USA): 
  
 
1- Invasive ductal carcinoma- 76%. 
2- Invasive lobular Carcinoma – 8%. 
3- Ductal/lobular carcinoma-7%. 
4- Mucinous (Colloid) carcinoma- 2.4%. 
5- Tubular carcinoma- 1.5%. 
6- Medullary Carcinoma- 1.2%. 
7- Papillary carcinoma- 1%. 
Other subtypes, including metaplastic breast cancer, invasive micropapillary 
breast cancer,  Adenoid Cystic carcinoma, Paget disease of the breast and 
inflammatory carcinoma, all account for fewer than 5% of cases.(3) 
Invasive ductal carcinoma:  
Invasive ductal carcinoma is the most common type of invasive breast cancer, 
accounting for 70-80% of invasive lesions. It is also termed invasive carcinoma 
of no special type or invasive carcinoma not otherwise specified (NOS). 
On gross pathologic evaluation, these lesions are typically hard, gray-white, 
gritty masses on gross pathologic examination which invade the surrounding 
tissue in a haphazard fashion to create the characteristic irregular, satellite 
shape. They are characterized microscopically by cords and nest of tumor cells 
with varying amount of gland formation and cytological features that range 
from bland to highly malignant.  
  
 
The malignant cells induce a fibrous response as they infiltrate the breast 
parenchyma , and this reaction is, in large part, responsible for clinically and 
grossly palpable mass, the radiologic density, and solid sonographic 
characteristics of typical invasive carcinomas. 
Invasive ductal carcinomas are divided into three grades based upon a 
combination of architectural and cytological features, usually assessed utilizing 
a scoring system based on three parameters: 
1- Well-differentiated (grade 1):  Well–differentiated tumors have cells that 
infiltrate the stroma as solid nests of glands. The nuclei are relatively 
uniform with little or no evidence of mitotic activity. 
2- Moderately differentiated (grade 2): Well-differentiated tumors have cells 
that infiltrate as solid nests with some glandular differentiation. There is 
some nuclear plemorphism and moderate mitotic activity. 
3- Poorly differentiated (grade 3):  Poorly differentiated tumors are 
composed of solid nest of neoplastic cells without gland formation. There 
is marked nuclear atypical and considerable mitotic activity. 
A variable amount of associated ductal carcinoma in situ (DCIS) is present in 
most. The extent of DCIS but not lobular carcinoma in situ (LCIS) is an 
important prognostic factor in patients treated with breast conversing therapy, 
  
 
in which the surgical goal is complete excision of both intraductal and invasive 
carcinoma. 
Invasive lobular carcinoma:  
The morphological features of invasive lobular carcinoma, (ILC), classical type 
are characterized by small, round cells that are bland in appearance and have 
scant cytoplasm, which infiltrate the stroma in single file and surround benign 
breast tissue in a targeted manner. Infiltration typically does not destroy 
anatomic structure or incite a substantial connective tissue response. 
Tubular Carcinoma:   
Tubular carcinomas were relatively infrequent in pre-mammography era, 
accounting for 2% or less of invasive breast cancers. However, in some series 
of mammographically screened population the incidence is higher, accounting 
for 10% to 20% of invasive cancers. 
Tubular carcinoma is characterized by the presence of well-formed tubular or 
glandular structures infiltrating stroma. 
1- The tubules tend to be elongated, and many have pointed ends. 
2- The cells composing the tubules are cuboidal to columnar and often have 
apical cytoplasmic protrusion or ''snouts''. 
3- The tumors cells are cytologically low grade. 
  
 
4- Associated DCIS, typically of low grade type, is present in about three-
quarters of the cases. 
These lesions have a relatively favorable prognosis compared to infiltrating 
ductal carcinoma; the natural history is indolent and metastases are rare. 
Mucinous (colloid) carcinoma: 
Mucinous carcinomas account for 1-2% of invasive breast cancers and appear 
to be more common in older patients. These lesions usually have a soft 
gelatinous appearance on gross examination, and they tend to be well 
circumscribed. They are characterized microscopically by nests of tumor cells 
dispersed in large pools of extracellular mucus.  
The cells tend to have uniform, low grade nuclei. Similar to tubular 
carcinomas, these lesions also represent a prognostically favorable variant of 
invasive breast carcinoma. 
Medullary carcinoma: 
Medullary carcinoma account for anywhere from 1-10% of invasive breast 
cancers. However, there is considerable interobserver variability in the 
diagnosis of this type of breast cancer which is, at least in part, dependent upon 
the classification system employed. 
Medullary carcinomas are well circumscribed on macroscopic examination and 
are often soft and tan-brown with areas of haemorrhage or necrosis. 
  
 
Circumscription of the lesion is also evident microscopically. The tumor cells 
are poorly differentiated (high-grade), grow in a syncytial pattern and have an 
intense associated lymphoplasmacytic infiltrate, and this tumor is actually quite 
rare if strict diagnostic criteria are followed. 
Medullary and medullary-like carcinomas occur more frequently in younger 
patients than other types of breast cancer. They are also more frequent in 
women who inherit mutations of the BRCA-1 gene (10% of breast cancers are 
medullary in this population, as compared to <1% of non-BRCA-1 gene-
related breast cancers). However, the majority of breast cancers in patients with 
BRCA-1gene mutations (90%) are not medullary. The prognosis for pure 
medullary carcinomas appears to be somewhat more favourable than that of 
infiltrating ductal carcinomas, despite their aggressive histologic appearance. 
1.3. Other histological and clinical types:  
A number of other histologic types account for the remaining invasive breast 
cancers. These include invasive micropapillary carcinoma, metaplastic 
carcinoma, adenoid cystic carcinoma and others. Special types of presentation 
of breast carcinomas, including paget disease and inflammatory carcinoma and 
other histologies arising in the breast (lymphomas, sarcoma and phyllodes 
tumors). 
 
  
 
Micropapillary carcinoma: 
 Invasive micropapillary carcinoma is a particularly aggressive form of cancer 
that has a proclivity for lymph node metastasis even when small in size. 
Metaplastic carcinoma: 
Metaplastic carcinoma is a well circumscribed tumor that consists of various 
combinations poorly differentiated ductal adenocarcinoma, mesenchymal 
(sarcomatous) and other epithelial (e.g., squamous cell) components. Whether 
these tumors have a worse prognosis than ordinary invasive ductal cancers is 
unclear. Some studies suggest that tumors in which the squamous cell 
component predinomates are aggressive and frequently treatment-refractory 
when compared to other invasive ductal cancers. However, because metaplastic 
breast cancer was not officially recognized as a distinct pathologic diagnosis 
until 2000, knowledge about treatment patterns and outcomes is limited. 
Despite the perception of a worse prognosis, all metaplastic breast cancers are 
treated similar to other invasive cancers. 
Adenoid cystic carcinoma: 
The rare adenoid cystic carcinoma of the breast has a distinctive histological 
pattern that is morphologically identical to adenoid cystic carcinoma found in 
the salivary glands (and other sites). This tumor tends to be associated with a 
  
 
favorable prognosis, even when tumor size is large; the reported incidence of 
axillary metastases in most series is less than 5%. 
 Histological grading based upon the percentage of solid areas (as is used for 
salivary gland tumors) has been suggested as being prognostically useful, 
although other disagree. At least two series in which outcomes were not as 
favorable in most reports were predominating by patients with higher-grade 
tumours (i.e., the solid variant). 
Inflammatory carcinoma: 
Inflammatory carcinoma is a distinct form of locally advanced breast cancer 
that is characterized clinically by erythema, oedema, and warmth of the skin 
breast. The histologic correlate of the clinical picture is dermal lymphatic 
invasion by tumour cells. The prognosis of this tumour is poor. 
Paget disease: 
Paget disease is a disorder of nipple and areola, characterized clinically by an 
eczematiod appearance with crusting, scaling or erosion.  
 Histologically, there are breast cancer cells within the nipple and areolar 
epidermis. This lesion is virtually always associated with underlying mammary 
carcinoma which may be either in situ or invasive.(2, 3)  
 
 
  
 
1.4. Microscopic pathology for invasive breast carcinomas: 
 Histologic grade: 
 The microscopic architecture (growth patterns) in the majority of infiltrating 
carcinomas is variable and often mixed, although a particular pattern may 
predominate. The architecture reflects the degree of differentiation. Tubules, 
cribriform glands, irregular glands, papillae and acini occur in well-
differentiated tumours. Cords are common in intermediate grade of tumours. 
Solid nests and sheets predominate in poorly-differentiated neoplasms.  
The nuclear grade is determined by:  
1. Uniformity or irregularity of nuclear size and shape.  
2. Chromatin particle size (finely or coarsely granular) and distribution 
(even or uneven).  
3. Nucleoli (size and frequency).  
4. Mitotic activity.  
In general, there is a good correlation between the architecture and the nuclear 
features. Those well-differentiated tumours have predominantly glands and 
uniform tumour cells with small nuclei, fine chromatin, inconspicuous nucleoli 
and low mitotic activity. Whereas poorly differentiated tumours have mostly 
nests and sheets present with large, irregular nuclei, coarse chromatin, 
prominent nucleoli and high mitotic activity. Moderately differentiated 
  
 
neoplasms are intermediate between the two groups. Because of the 
heterogeneity within the same tumour, it would be advantageous to adopt a 
uniform, reproducible system that correlates with prognosis. The 
Bloom/Richardson (Elston Modified) grading method is one such system. It 
combines the architecture and nuclear scores into a final histologic grade. This 
System is recommended for all invasive carcinomas (Page, et al). 
Bloom/Richardson (Elston modified) grading method: 
Tubular Formation Score 
Majority of tumour (>75%) 1 
Moderate Degree (10-75%) 2 
Little or none (<10%) 3 
Nuclear Pleomorphism Score 
Uniform Cells (size is not criterion) 1 
Moderate Increase in Variability 2 
Marked Variation (Often large nucleoli) 3 
Mitotic Counts (per 10 high power fields) Score 
Low (0-5 mitotic figures) 1 
Moderate (6-10 mitotic figures) 2 
High (>11 mitotic figures) 3 
Final grade Score 
Grade I, Well differentiated 3-5 points 
Grade II, Moderately differentiated 6-7 points 
Grade III, Poorly differentiated 8-9 points 
 
  
 
Stromal changes:  
These include desmoplastic reaction with proliferation of newly formed 
fibroblasts in an edematous, myxomatous or highly collagenized matrix. In the 
background, elastosis also occurs. The number of lymphocytes, plasma cells 
and histiocytes is variable.  
 Vascular lymphatic space invasion:  
This feature should be carefully evaluated and reported. Shrinkage artefact due 
to fixation produces an empty space between the tumour nest and fibrous 
stroma. This space is often mis-interpreted as vascular lymphatic space. A true 
vascular lymphatic space is lined by clearly recognizable endothelial cells.  
Invasion is most readily seen in the periphery of the tumour and beyond. Less 
commonly, the tumour cells invade the blood vessels and perineural spaces.  
Studies have demonstrated that the presence of vascular lymphatic space 
invasion increases tumour recurrence. The study of (Rosen et al) further 
reveals that invasion of the lymphatic, capillaries and blood vessels  in tumours 
up to 2 cm in size with or without lymph node metastases increases death rate, 
when compared to comparable tumours without such a finding (Rosen PP et al, 
1981). Perineural space invasion does not have prognostic significance by 
itself. 
 
  
 
Invasive ductal carcinoma with extensive intraductal component (EIC): 
Within the infiltrating ductal carcinoma, the intraductal carcinoma may be 
extensive or completely absent. It is important to assess the amount of 
intraductal carcinoma. Extensive intraductal component (EIC) positive tumors 
include the following conditions. 
1. Predominantly invasive carcinoma containing DCIS in more than 25% of 
tumour. 
2. Predominantly DCIS with focal invasion and DCIS extend beyond the 
borders of invasive carcinoma.  
When treated by conservative surgery and radiotherapy, these EIC positive 
tumours are more likely to recur than EIC negative tumours. Based on data 
from Joint Center for Radiation Therapy, 28% of recurrent invasive ductal 
carcinomas are EIC positive. Five-year actuarial local recurrence rate is 6% 
and 24% for EIC negative and positive tumours, respectively.     
1.5. Prognostic factors of invasive breast carcinoma: 
A. Tumour size. 
B. Histologic and nuclear grades by Bloom/Richardson (Elston Mod.) Grading 
Method.  
C. Presence of lymphatic space invasion.  
  
 
D. Surgical margin: When treated by conservative surgery and radiotherapy, 
the local recurrence rate is 3% when margin is cleared of tumour by more 
than 1 mm, 2% when margin is cleared by less than 1 mm, 9% when the 
margin is positive in less than three low power fields, and 28% when the 
margins is positive in more than three low power fields (Joint Center for 
radiation therapy). 
E. Lymph node status: The lymph node status is one of the most important 
prognostic indicators. In addition, the number of lymph node involved, less 
than three or four and more, and the amount of metastasis further influence 
the survival. Tumour cells enter the lymph node via afferent lymphatics. 
For this reason, metastasis in the early stage occurs predominantly in the 
subcapsular region. With growth, tumor cells spread to the surrounding 
extranodal fibroadipose tissue and blood vessels. Extracapsular spread is 
reported to adversely affect the outcome.  
1.6. Additional prognostic markers by immunochemistry and 
flow cytometry: 
A. Estrogen Receptor (ER), Protein and Progesterone Receptor (PR) 
Protein: 
 ER positivity is favorable prognostic indicator; PR positivity alone is a weak 
favorable prognostic indicator. Patients with ER positive metastatic tumour 
  
 
receiving endocrine therapy had 60% overall clinical response, and 20% 
reduction in recurrence/mortality (Early Breast Cancer Trialists' Collaborative 
Group). When ER and PR are combined, the frequency and response rates are 
summarized as follows (McGuire, et al): 
Status Frequency Response rate 
ER+/PR+ 58% 77% 
ER+/PR- 23% 27% 
ER-/PR+ 4% 46% 
ER-/PR- 15% 15% 
 
ER/PR status has been based on biochemical ligand assay, which requires fresh 
tissue frozen immediately following excision. ER/PR status can be obtained on 
formalin embedded tissue sections by immunohistochemical stains using 
monoclonal antibodies. 
There is 80-90% agreement between biochemical ligand assay and 
immunohistochemical stains for ER/PR. The result of the latter is reported by 
the percent of positive tumour cells. Immunohistochemical stains for ER/PR 
have several advantages: precise localization, accurate quantification by visual 
estimates or by digital imaging technique, possible to perform on routinely 
processed tissue and archival paraffin block from earlier surgery, workable on 
cells in effusion or smears obtained by fine needle aspiration. However, 
  
 
laboratory agreement on the type of antibody to use and scoring method is 
needed. 
B. HER-2/neu Oncogen: HER-2/neu is an oncogen and its protein product is 
located on the cell surface. It may influence growth factor receptor and 
promote cellular differentiation, adhesion and motility. It is detected by 
immunohistochemical stain on tissue section. Amplified or over-expression 
is seen in 20-30% of breast cancers). 
HER-2/neu over-expression is a predictive marker for resistance to adjuvant 
therapy (cytoxan/methotrexate and tamoxifen). 
HER-2/neu is over-expressed in high grade DCIS only, therefore cannot be 
used to distinguish low grade DCIS from atypical ductal hyperplasia.  
C. P-53: Tumour suppressor gene and its protein product is a nuclear 
transcription factor related to cell cycle regulation and apoptosis. It is 
detected by immunohistochemical stain on tissue section. Abnormal p53 
phenotype in tumour is associated with poor clinical outcome among node 
negative patients 
D. Flow DNA cytometry: By flow cytometry, the DNA ploidy patterns and 
ploidy levels of the stem cells and their cell cycle kinetics can be 
determined. Isolated tumour cells are obtained from the solid tumour by 
  
 
mechanical dispersion or enzyme dissection. Most laboratories currently 
use tumour tissue embedded in paraffin block. 
The tumour cells are stained with dye specific for DNA suspended in fluid and 
passed through the laser beam. The DNA content is plotted in a histogram. 
Benign tissue in the same specimen is processed similarly to serve as diploid 
control. The Go/G1 peak represents cells in the resting phase. As cells begin to 
synthesize DNA, the DNA content is increased (S-phase). At the completion of 
DNA duplication, G2 and M (mitotic) cells produced a second peak with 
double amount of DNA. 
The ploidy level of stem cells is compared with benign diploid cells in the form 
of DNA index. To allow for instrument error of 5%, the diploid tumours' have 
DNA index of 0.95 to 1.05, tetraploid tumours' 1.90 to 2.1). Flow DNA 
cytometric analysis provides an objective measure of DNA/chromosome 
abnormality and rate of cellular proliferation in a more consistent manner than 
subjective evaluation of histologic features.  
In the study of stage I-III breast cancers by Kallioniema et al., the 6-year 
survival rates for patients with diploid tumour is 80%, tetraploid tumours' 60%, 
hyperdiploid aneuploid tumors (DNA index 1.05-1.8) about 55%, and 
hypertetrapolid aneuploid tumours' 40%. When DNA index and S-phase 
fraction are combined, the best survival is found among patients with diploid 
  
 
tumours' and S-phase fraction of less than 7%. The lowest survivals are those 
with aneuploid tumours' with S-phase fraction of greater than 12%. The 
remaining tumours' have intermediate prognosis.(2, 3,4) 
1.7. Clinicopathlogic characteristic of invasive lobular carcinoma 
of the breast: 
Knowledge about the biological, clinical and pathological characteristics of 
invasive lobular carcinoma of the breast has remained complex and unclear due 
to rarity of such cases. 
In 1941, Stewart et al. proposed that entity of lobular carcinoma as a type of 
breast cancer. They described both an invasive form and in situ form of the 
disease which was confined to lobule and terminal ducts.(2) 
Invasive lobular carcinoma (ILC) is the second most common type of invasive 
breast cancer after invasive ductal carcinoma, and accounts for 5-15% of all 
breast cancer in Europe and United States, respectively. The incidence of 
invasive lobular carcinoma in Japan was approximately 1-4% among all breast 
cancers.(7) 
A recent epidemiologic study indicated that the incidence of this type of breast 
cancer is increasing especially among the postmenopausal women.(6,7) Reports 
indicated that the use of combined oestrogen and progesterone hormone 
  
 
replacement therapy increased the risk of all types of breast cancer, especially 
invasive lobular carcinoma.(7)  
 Incidences rates of lobular cancer are rising faster than the rates of ductal 
carcinoma (USA), and postmenopausal hormone therapy may be more strongly 
related to lobular cancer risk than ductal cancer risk.(9) 
The variation in reported incidence is most probably due to different 
histopathological criteria used to define invasive lobular carcinoma rather than 
a real variation incidence. The definition of lobular carcinoma is based on 
cytomorphologic characteristics and absence of ductal formation.(4,17)  
Because invasive lobular carcinomas (ILC) lesions are less common and other 
several subtypes including alveolar, solid, tubulo-lobular, signet ring cell and 
pleomorphic subtypes, it is somewhat difficult to describe the clinical 
characteristics categorically. However, some of the clinical features have been 
reported to be (1) muliticentric development in the same or the adjacent breast 
proportions than other types of breast cancer, (2) ill-defined margins and subtle 
thickening or indurations observed in mammography (finding of architectural 
distortion), (3) more frequent expression of oestrogen receptors(ER) and (4) 
gastrointestinal and peritoneal metastasis. Although there are several 
differences in the clinicopathological characteristics of ILC and invasive ductal 
  
 
carcinoma, both types of carcinoma are usually managed using the same 
strategy.(4, 6,7)  
 A series comprises 301 consecutive classic lobular breast carcinomas seen at 
one institution between 1994 and 2001, compared to an equal number of 
invasive ductal carcinomas at the same institution during the same period, 
matched for year of surgery, age, menopausal status, primary tumor size, nodal 
involvement, hormone receptor status and where possible histological grade. 
Despite matching, the lobular carcinomas were more frequently multifocal, had 
more involved nodes, lower grade and lower proliferative fraction. There was 
no significant difference in disease-free or overall survival, locoregional 
relapse or time to distant metastasis between the lobular and the lobular group 
showed a trend to earlier appearance of contralateral breast cancer.(10,12)  
1.8. Gross pathology for lobular carcinoma: 
Invasive lobular carcinomas present mostly as an irregular, infiltrating, poorly 
delineated mass rather than a sharply demarcated lesion. Invasive lobular 
carcinomas often display multifocality in the ipsilateral breast and have a 
higher tendency to develop bilaterality than other tumor types. The size of the 
invasive component varies considerably (from millimeters to several 
centimeters). 
  
 
The edges of the tumor mass are often difficult to evaluate and may be best 
appreciated by palpation. The cut surface often appears as an inconspicuous, 
grey or white area. In other cases there is no grossly visible mass and the 
tumour can only be appreciated bypalpation or not at all. 
Some invasive lobular carcinomas have a macroscopic appearance identical to 
that of infiltrating ducatal cancers. However, in many cases no mass lesion is 
grossly evident, and the excised breast tissue may have a normal or only 
slightly greater firm consistency. Thus, the microscopic size of invasive lobular 
carcinoma may be significantly greater than that measured grossly.(3,4,6) 
1.9. General histological features for invasive lobular carcinoma: 
The original definition of invasive lobular carcinoma comes from Stewart and 
Foote, who described the classical infiltrative subtype. 
Invasive lobular carcinomas display characteristic cytologic features and a 
distinct infiltration pattern of the stroma. Classical invasive lobular carcinomas 
are composed of single cells, infiltrating in strands. In some cases focal tubule 
formation is seen.(4) 
 The classic pattern of invasive lobular carcinomas are characterized by a small 
uniform cell population, lacking cohesion and invading the stroma as 
individual tumor cells, resulting in a ‘single-file’ or Indian-file’ pattern of 
growth. Sometimes tumor cells are located around benign ducts in a circular 
  
 
fashion resulting in a targetoid appearance. Tumor cells usually have a round 
or oval nucleus, thin eccentrically cytoplasm, often containing intracytoplasmic 
lumina (Martinz, 1979). The nucleoli are usually absent or inconspicuous. 
Mitotic figures are rare. 
 The classical form of invasive lobular carcinoma is often accompanied by in 
situ lesions of lobular neoplasia occurring in 40–60% of invasive carcinomas. 
Invasive lobular carcinoma is sometimes accompanied by a prominent 
lymphocytic or granulomatous reaction. The histological diagnosis of classical 
lobular carcinomas requires at least70% of single file growth pattern.(2,3,4,8,11)  
1.10. Special subtypes of invasive lobular carcinoma:  
Several histological variants of invasive lobular carcinoma have been described 
previously (Fechner; 1975; Fisher et al., 1979; Martinz, 1979; Dixon el al., 
1982). Each subtype is named according to its growth pattern:(11)  
• Classical variant:  Infiltrates in a diffuse manner through tissues without 
architectural distortion and which has tumour cells that are arranged in 
narrow cords, so called ‘Indian files’, and that surround normal structures in 
targetiod fashion (Fechner, 1975; Martinez, 1979).  
•  Solid pattern: This pattern is characterized by sheets of uniform cells, 
lacking cohesion, resulting in a growth pattern in large confluent areas with 
little or absent stroma in between. 
  
 
•  Alveolar pattern: In this variation tumor cells are arranged in small clusters 
or nests of approximately 20 cells, separated by delicate fibrovascular septa. 
•  Trabecular pattern: This variant represents a histological overlap between 
classical and so called trabecular filing pattern. This morphological 
coincidence is due to the morphological similarity between ‘single file’ seen 
in the classical variant and ‘one-cell thick trabecules’ observed in the 
trabecular variant. 
•  Tubulolobular pattern: This lesion is composed of small tubular structures 
as well as of single cell files seen in classical lobular carcinomas. This 
category represents a morphological overlap between invasive tubular and 
invasive classical lobular carcinoma, traditionally categorized as a variant of 
invasive lobular carcinoma. 
•  Pleomorphic variant: This variant represents a distinct subtype of invasive 
lobular carcinoma with similar growth pattern and stroma infiltration as seen 
in other subtypes. However, the tumor cells are larger and exhibit more 
cellular atypia and pleomorphism. The cytoplasm is more abundant and it 
often shows some eosinophilia. Recurrence free survival is reportedly poorer 
in pleomoprhic lobular carcinomas than in classical lobular carcinomas. 
Pleomorphic lobular carcinomas can display apocrine, signet ring cell and 
  
 
histicytoid differentiation. Apocrine differentiation in invasive lobular 
carcinomas has been found to have an especially aggressive clinical course. 
•  Histiocytoid variant: In this variant tumor cells have a pale appearance with 
foamy cytoplasm and mild nuclear variation. 
•  Signet cell variant: This subtype occurs in invasive breast carcinomas with 
a growth pattern of a lobular carcinoma, consisting of a prominent 
component of signet ring cells. 
•  Mixed lobular carcinomas: This group shows an admixture of classical 
lobular carcinoma accompanied by at least one more additional pattern, 
which could be either a special type of invasive lobular carcinoma or of 
invasive ductal carcinoma.(4,8,11,13)  
1.11. Grading of invasive lobular carcinoma: 
Grading of invasive lobular carcinomas is widely accepted in routine surgical 
pathology despite the fact, that the application of BRE Score is somewhat 
special in this tumor type. There is no tubular formation in invasive lobular 
carcinomas; therefore, a score of 3 has to be attributed for tubule formation. 
Mitotic activity is usually low (score 1 or 2), nuclear pleomorphism can vary 
from monotonous to largely pleomorphic nuclei vary from monotonous to 
largely pleomorphic nuclei (score 1 to 3). Therefore, the majority of invasive 
lobular carcinomas are classified as grade 2, due to moderate nuclear 
  
 
pleomorphism and low mitotic rate. Classical lobular carcinomas can be graded 
as grade 1, if tumor cells exhibit round small monotonous nuclei. Pleomorphic 
lobular carcinomas can be also graded as grade 3 if sufficient mitotic figures 
are present.(3,4,8,13,17) 
1.12. Differential diagnosis for invasive lobular carcinoma: 
Lymphatic proliferation: 
Invasive lobular carcinomas can closely resemble an atypical lymphatic 
proliferation. This diagnostic challenge preferentially occurs with suboptimal 
tissue fixation. 
The use of immunohistochemistry (cytokeratin the neoplastic cells) or the 
detection of cytoplasmic in vacuoles containing mucin, should easily identify 
the lesion as invasive lobular carcinoma. Rarely, inflammatory cells can mimic 
invasive lobular cancer cells, which can be challenging particularly on frozen 
sections. The evidence of in situ components, lobular neoplasia, may be helpful 
in such settings.(4,16) 
Invasive ductal carcinoma: 
The distinction between lobular and ductal carcinomas can pose a diagnostic 
difficulty based on histology alone. Invasive ductal carcinomas can display a 
growth pattern similar to invasive lobular carcinomas since tumor cells 
spreading in single files can occur in invasive ductal carcinomas. The evidence 
  
 
of peri- or intratumoral lobular neoplasia (LN) or ductal carcinoma in situ 
(DCIS) may be of some help, however this is of limited value as in- situ 
components can be present independently of the histology of the invasive 
component. Intracytoplasmic vacuoles and areas of single cell infiltration favor 
the diagnosis of invasive lobular carcinoma. Immunostains for E-Cadherin, 
hormone receptors, gross-cystic disease fluid protein, p120 can carcinoma. 
Immunostains for E-Cadherin, hormone receptors, gross-cystic disease fluid 
protein, p120 can support the correct diagnosis.  
Generally, the absence of E-Cadherin expression on the cell membrane and in 
most cases strong hormone receptor expression favour the diagnosis of 
invasive lobular carcinoma. 
 In addition to their different histologic appearance and mammographic 
characteristics, there are distinct prognostic and biologic differences between 
infiltrating lobular and ductal cancers. 
1. Infilterating lobular carcinomas have a higher frequency of bilaterality and 
mulicentricity than infilterating ductal carcinoma. 
2. Infilterating lobular carcinomas arise in older women and are larger and 
better differentiated tumors. As a rule invasive lobular carcinomas are ER-
positive, with variant lesions showing occasional variable expression. 
  
 
3. While older series report as similar prognosis for infiltrating lobular cancer 
and invasive ductal lesion, more recent reports suggest that  outcomes (at 
least in the short-term) may be more favorable for lobular cancers and 
improving over time. However, variants of infiltrating lobular carcinomas 
exist, some of which have poor prognosis. 
4. As a group, invasive lobular carcinomas tend to metastasize later than 
invasive duct carcinomas and spread to unusual locations such as 
peritoneum, meninges, and the gastrointestinal tract. 
Lobular breast cancers have been observed to occur in 20% to 54% of women 
from families who carry mutations in the E-cadherin (CDH1) gene, which is 
associated with hereditary diffuse type gastric cancer. Approximately 50% of 
sporadic lobular breast cancers have E-caderin mutations.(3,4,6,7) 
Fat necrosis: 
The histiocytoid variant of invasive lobular carcinoma may be particularly 
difficult to differentiate from fat necrosis in some instances, as tumor cells can 
mimic reactive histiocytic infiltration and vica versa. Immunohistochemistry 
for macrophage markers (e.g. CD 68) and cytokeratins should lead to the 
correct diagnosis.(4) 
 
 
  
 
1.13. immunohistochemistry: 
Hormone receptors: 
The large majority of invasive lobular carcinomas show strong expression of 
estrogen and progesterone receptors, a higher rate than in invasive ductal 
carcinomas.(3,7,11) 
Her2 gene and protein: 
 Her 2 protein expression and/or gene amplification are rare events in invasive 
lobular carcinomas. The pleomorphic variant of invasive lobular carcinomas 
represents an exception to this rule, as Her2 gene amplification and protein 
expression, particularly in grade 3 cases have been described in the 
literature.(3,6) 
Proliferation index (MIB-1): 
Proliferation index is generally low in invasive lobular carcinomas. In some 
studies distinct differences in proliferation activity were detected in classical 
versus pleomorphic subtypes varying from 2.9% (classical type) to 8–11% 
(pleomorphic variants). The proliferation fraction of invasive ductal 
carcinomas is usually higher; in grade 3 cases the MIB-1 labeling index often 
reaches 25–30% or even higher.(4) 
 
 
  
 
E- Cadherin: 
The transmembrane protein E-Cadherin which mediates cell-cell adhesion and 
acts as an invasion suppressor factor had been reported to be a reliable marker 
in the differentiation of ductal and lobular breast carcinomas. Ductal 
carcinomas usually express membranous E-Cadherin reactivity, while invasive 
lobular carcinomas are mostly negative. Therefore, the absence of E-Cadherin 
positivity is a significant finding in the diagnosis of invasive lobular 
carcinomas. Together with conventional histology, a negative E- Cadherin 
reaction is the most helpful immunhistochemical marker conversely, in a 
subset of poorly differentiated invasive ductal carcinomas (less than 15%), E-
Cadherin may be absent. In these cases other morphological features such as 
tubule formation, hormone receptor status and additional 
immunohistochemistry are needed to confirm the diagnosis of an E-Cadherin 
negative invasive ductal carcinoma.(3, 4, 6, 8,11) 
P120: 
The interaction of E-Cadherin with catenins such as p120 has been documented 
in previous studies. Cytoplasmic positivity for p120 generally favors the 
diagnosis of lobular carcinoma, as membranous reaction has mostly been 
reported in invasive ductal carcinoma.(3,4) 
 
  
 
GCDPF-15 (gross cystic disease fluid protein): 
Approximately one third of the invasive lobular carcinomas are positive for 
GCDFP-15, a marker for apocrine differentiation. Invasive lobular carcinomas 
with histiocytoid, pleomorphic or signet ring cell components tend to express 
GCDFP-15. Positivity for this marker however does not necessarily confirms 
the diagnosis of invasive lobular carcinoma, as GCDFP-15 can be seen in other 
breast cancer subtypes such as apocrine, endocrine, oncocytic and acinic cell 
carcinomas and some positivity has been reported in invasive ductal 
carcinomas as well.(4) 
Cytokeratin:  
Invasive lobular carcinomas are reportedly negative for cytokeratin.(5,6) In 
recent studies a subset (15%) of invasive lobular carcinomas tested positive for 
cytokeratin/6, which also were preferentially hormone receptor negative, 
leading to postulating a distinct basal like ILC subtype. However, no definite 
morphological differences could be found upon cytokeratin 5/6 positivity 
among invasive lobular carcinomas.(3,10,12,13)       
Cyclin D1: 
Cyclin D1 can evoke hormone receptor activation through binding to estrogen 
receptors. Overexpression of Cyclin D1 has been reported in over 80% of 
  
 
invasive lobular carcinomas. However, this positivity is not specific for a 
definitive lobular differentiation, as it can occur in other subtypes as well.(4,10) 
1.14. Prognoses for invasive lobular carcinoma: 
In general, prognosis of invasive lobular carcinomas does not consistently 
differ from invasive ductal carcinomas. However when histological subtypes of 
ILC are analyzed one by one, a more favorable outcome has been reported for 
the classical type of invasive lobular carcinoma. In some studies, the 
pleomorphic and the signet ring cell variants have been associated with poorer 
outcome. Also, the metastatic pattern of invasive lobular carcinomas differs 
from invasive ductal breast carcinomas. Higher rates of bone, gastro-intestinal 
tract, meningeal and/or ovarian metastases have been documented in invasive 
lobular carcinomas.(4,6,7,15,16)   
In a study of 230 patients with stage 1 and 11 invasive lobular carcinoma 
treated by mastectomy and axillary lymph node dissection, 176 showed the 
classical or Indian file pattern of (ILC) and 54 patients showed variant 
histology (solid), alveolar, and mixed partterns). ILC (Classic) patients were 
younger than variant patients, and more likely to be premenopausal.(10) 
Invasive lobular carcinoma (ILC) of classical or Indian –file microscopic 
architectural pattern is approximately 85%-90% and of more favourable 
prognosis than variant subtypes of ILC.(11) 
  
 
In one study of 138 patients had presented with invasive lobular carcinoma 
(ILC) over a period of 20 years. Histological subtypes of ILC and vascular 
invasion played a role in the biologic behaviour of the tumour .interestingly 
premenopausal status protected against the risk of relapse, while being 
postmenopausal, increased the risk.(12) 
  One hundred and seventy-one cases of operable invasive lobular carcinoma, 
presenting over an11-year period, were reviewed. Histological subtypes were 
investigated to determine differences in their clinical behaviour and whether 
these differences could be explained by histopathological features. 
Five subtypes were identified: mixed (45.6%), classical (30.4%), tubulo-
lobular (13.5%), solid (6.4%) and alveolar (4.1%). The tubulo-lobular tumours 
were more likely to be of good histological grade and node negative. 
The other three subtypes did not differ significantly in their histopathological 
parameters, reflected in similar clinical behaviour. They occupied an 
intermediate position between the other two subtypes in terms of 
prognosis.(4,10,11,12) 
 
 
 
 
  
 
OBJECTIVES 
 
General objectives:   
 To highlight the clinico-pathological characteristics of invasive lobular 
carcinoma of the breast; and to identify the incidence rate at National Health 
Laboratory (NHL), from 2005 to 2009. 
 
Specific objectives: 
• To study morphological features of invasive lobular carcinoma of the breast 
(ILC). 
• To outline the clinical characteristics of invasive lobular carcinoma (ILC). 
• To compare the incidence rate of invasive lobular carcinoma with other 
invasive carcinomas of the breast. 
• To identify the estrogen and progesterone receptors(ER/PR) status of ILC. 
 
 
 
 
 
  
  
 
2. MATERIALS AND METHODS 
 
Study design:  
This is a descriptive, archival and retrospective study.   
Study area:  
The study conducted at National Health laboratory in Khartoum (NHL); over 
period of five years (2005- 2009).  
All file recorded cases of invasive carcinoma of the breast were collected and 
reviewed to identify the incidences rates; and with special consideration on 
clinophalological features of invasive lobular carcinoma. 
Materials: 
The clinical and histological data of patient’s records, from the National Health 
Laboratory in the Sudan were collected and reviewed.  
A total of 508 patients from archives pathology reported files as Invasive 
breast carcinoma from period over five years (2005- 2009) were collected. The 
data collected includes age, type of specimen (i.e. Mastectomy or/and biopsy 
specimens), histological type and grade, lymph node involvement and 
hormonal status (ER & PR).   
  
 
Haematoxylin and eosin stained glass slides from formalin fixed, paraffin 
embedded tumour tissue in 33 of 508 patient diagnosed as invasive lobular 
carcinomas of the breast.  
Criteria of selection: 
All archive pathology reported as invasive lobular carcinoma in National 
Health Laboratory records during years 2005- 2009 were included in the study. 
The data collection sheet designed to include patient’s clinical information, 
specimen type, histological type, histological malignancy grade, lymphatic 
invasion and hormonal receptors status. 
Other invasive breast carcinoma (invasive ductal, special histological and 
clinical subtypes) and male invasive lobular carcinoma are excluded in this 
descriptive, retrospective study.    
Methods: 
The clinical and pathological characteristics of 33 patients with invasive 
lobular carcinoma who underwent surgery were reviewed. All the sections 
obtained from formalin fixed, paraffin-embedded blocks of surgical specimens 
were stained by H & E for histological evolution and immunohistochemical 
staining for Estrogens and progesterone receptor (ER &PR) were re-examined 
by light microscopy. 
  
 
The evaluation of the 33 invasive lobular carcinoma (ILC) include recording of 
the following features: Diagnosis or histological type and classified subtypes, 
histological malignancy grade, vascular and lymphatic invasion and hormone 
receptors for tumour characterization. Regarding the diagnosis, two categories 
were used: Classical ILC subtypes and other non- classical subtypes (Solid, 
tubulo-lobular, pleomorphic, and singnet ring cells, alveolar and mixed 
subtype). Histological malignancy grading was performed according to the 
modified Bloom and Richardson grading system where the combination of 
three histological features was evaluated: Percentage of tubules formation, 
nuclear pleomorphism and mitotic count. Multifocality was defined by at least 
two tumour foci apart.  
During the histological assessment of 33 cases of invasive lobular carcinoma, 3 
cases were ruled out (excluded) and categorized histologically as invasive 
ductal carcinoma special subtypes. ER and progestrone receptor (PR) in the 
malignant tissue were measured by an enzyme immunoassay, or 
immunohistochemical staining of sections taken from formalin-fixed, paraffin-
embedded blocks of surgical specimens. 20 sections were assessed for 
hormonal receptors and others 10 from patient’s files records.  The 
determinations of levels of hormone receptors were considered positive at least 
10% or greater of the nuclei of the tumour cells in the invasive part of the 
  
 
tumour, show a detectable positive reaction in oestrogen and/or progesterone 
receptor staining.  
Statistical analysis: 
 The data were analyzed using a computer statistical software called SPSS 
(originally, statistical package for the Social Sciences) to determine the 
frequency and percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3.  RESULTS 
From a total of 508 archived file reported pathology of invasive breast 
carcinomas between 2005- 2009 at national health laboratory. We identified 
411(80.9%) patients with invasive ductal carcinoma (IDC), 30(5.9%) patients 
invasive lobular carcinoma (ILC) and 67(13.2%) patients with others 
histological and clinical types of breast carcinomas (Table 1). 
On the studied materials 30(5.9%) of invasive lobular breast carcinoma 
27(90%) were classical types and 3(10%) recognized as signet ring and 
pleomorphic subtypes. The other variants of invasive lobular breast carcinoma 
(solid, alveolar, tubulo-lobular, pleomorphic and mixed) were not identified in 
the evaluated material in this study.  
The incidence rates of both invasive ductal and lobular carcinoma match with 
most of the reported studies regardless of variability of provided materials for 
analysis. It is realized in this descriptive study, there is a significant increased 
incidence of mastastatic carcinomas, 13(2.5%) of all invasive breast 
carcinomas, to the breast without identifying the primary or original sites 
(Table 2). 
The average age of the patients was 57.5 years (range, 30-85 years) and 
5.3(range, 25-82 years old) in patients with invasive lobular carcinoma, and 
other types of invasive breast cancers (Invasive ductal and other special types), 
  
 
respectively. The majority of patients falls in range of age (40-49 years), 
163(32.1%) for all invasive breast carcinomas, and 12(40%) of invasive 
lobular carcinoma.  Significantly, in the subject include 30 patients of invasive 
lobular carcinoma, 18(60%) were in postmenopausal age, while 12(40%) at 
premenopausal age (Table 3). 
Regarding the histological malignancy grade in all invasive breast carcinomas, 
grade 1 were 58(11.4%), grade 2 comprises 196(38.6%), grade 3, 135(26.6%) 
and 111(21.9%) not determined or classified (Figure 3). 
The histological malignancy grade in invasive lobular carcinoma of the 30 
histologically evaluated materials are categorized as grade 1, 5(16.7%), grade 
2, 22(73.3%), and grade3, 3(10%). Most of the tumours are grade 2(table 3). 
This is not suppressing considering the grading method and tumour 
morphology. The invasive lobular carcinoma is mostly of classical subtypes 
which consist of rather small tumour cells, growing in single filling without 
tubule formation. The number of mitosis is limited, which leaves the nuclear 
plemorphism as determining factor.  
In relation to age distribution with tumour histological grade in invasive 
lobular carcinoma, considerable number patients lies in age range of 40-49 
years, 12(40%) and postmenopausal age (Table 3). 
  
 
Invasion of lymphatic especially axillary group of lymph node is a significant 
pathological characteristic of most of invasive breast carcinomas. Regarding 
lymph node status, in the studied materials 160(31. 5%) patients with lymph 
node involved and 324(63.8%) revealed no involvements (Figure 5).  
In the evaluated (30) patients of invasive lobular carcinomas 12(40%) lymph 
node involved compared to 18(60%) with no involvements (Table 4).  
If lymph node status is compared to histological malignancy grade, there is a 
significant correlation, showing increased number of positive lymph nodes 
among the grade 2 tumours. 
8(67%) out of 12 lymph node involved with invasive lobular carcinoma, are 
grade 2, and 4(33%) grade 3. 
Relating lymph node status in invasive lobular carcinoma to age distributions, 
relative numbers of tumours are in age range of 40-49 years, 5(42%) lymph 
node involved and 7(58%) no involvement. Similarly, 5(42%) and 7(58%) of 
lymph node involved are in the postmenopausal and prememopausal age 
respectively. 
The percentage of lymph node metastasis tends to be lower in invasive lobular 
carcinoma as well as in the all invasive breast cancer. 
From 508 patients 225(44.3%) of invasive breast carcinomas were asses for 
hormone receptors, while 277(54.5%) not assesses (Figure 5). Similarly, 
  
 
30(100%) of invasive lobular carcinoma of the breast were evaluated for 
hormone receptors. Invasive lobular breast carcinoma predominantly is a 
hormone receptor positive, regardless of type. However, there is significant 
correlation between hormone receptor status and grade, with increased 
incidence of receptor positive tomours 15(50%) with grade 2 and negative 
tumours among grade 3.  
The proportion of ER and PR positive tumours was 21(70%), and 15(50%) and 
negative 9(30%) and 15(50%) in the invasive lobular carcinoma (Table 5).  
The tumours reactivity for hormones receptors (ER and PR) are categorized as 
ER/PR positive, 12(40%), ER+/PR-, 9(30%), ER-/PR+, 3(10%), and ER/PR 
negative 6(20%) in the studied materials for invasive lobular carcinoma (table 
6). The determination of levels of hormone receptors is considered positive 
when at least 10% or greater of the nuclei of the tumour cells in the invasive 
part of tumours. 
 
 
 
 
 
 
  
 
Table 1: Incidence rates of histological types of Invasive breast carcinomas 
(n = 508) 
Histologic type Frequency Percent 
 IDC 411 80.9 
 ILC 30 5.9 
 Others 67 13.2 
 Total 508 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2: Distribution of special histological and clinical types of breast 
carcinoma malignancies (n = 67) 
Special subtypes  Frequency percentage 
Intraducal carcinoma (In-Situ) 12 2.4% 
Invasive papillary carcinoma 8 1.6% 
Invasive mucinous carcinoma 7 1.4% 
Medullary breast carcinoma 5 0.9% 
Metaplastic carcinoma 4 0.8% 
Metastastic carcinoma 13 2.5% 
Malignant phylliodes tumours 4 0.8% 
Anaplastic carcinoma 3 0.6% 
Malignant mesenchymal tumours 2 0.4% 
Inflammatory carcinoma  3 0.6% 
Squemous cell carcinoma 1 0.2% 
Secretory carcinoma 3 0.6% 
Tubular breast carcinoma 2 0.4% 
Total 67 13.2% 
 
 
 
  
 
 
Table 3:  Correlation of age with the histological grade of invasive lobular 
carcinoma in study sample (n = 30) 
Age (in years) Histological Grade Total 
1 2 3 
20 -29 0 1 0 1 
30 - 39 0 3 1 4 
40 - 49 4 7 1 12 
50 - 59 1 4 0 5 
60 - 69 0 3 1 4 
70 - 79 0 2 0 2 
80 - 89 0 2 0 2 
Total 5 24 3 30 
 
 
 
 
 
 
 
  
 
 
Table 4:   Status of the lymph node involvement among patients with ILC 
(n=30)       
 Lymph node status Frequency Percentage 
Involved 12 40.0 
Not Involved 18 60.0 
Total 30 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 5: Shows the proportion percentage of ER and PR status in studied 
population 30 patients with ILC 
ER/PR Status Frequency Percentage 
+ ER 21 70% 
- ER 9 30% 
+ PR 15 50% 
- PR 15 50% 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 6: Summarized the combined ER and PR frequency and responses 
in ILC 
ER/PR Status Frequency Percentage 
+ ER/+PR 12 40% 
+ ER/-PR 9 30% 
-ER/+ PR 3 10% 
-ER/-PR 6 50% 
Total 30 100% 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1: Distribution of malignant breast conditions (n = 508) 
80.9
5.9 13.2
0
10
20
30
40
50
60
70
80
90
P
er
ce
nt
ag
e
IDC ILC Others
 
 
 
 
 
 
 
 
 
Histological type 
  
 
 
Figure 2: Age distribution in all invasive breast carcinomas (n = 508) 
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Figure 3: Distribution of histological grade of all invasive breast 
carcinoma (n = 508) 
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Figure 4: Distribution of the histological grade of invasive lobular 
carcinoma (n = 30) 
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Figure 5:  ER/PR status of all invasive breast carcinomas among the study 
population (n = 508) 
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Figure 6: Lymph nodes status of invasive breast carcinoma among the 
study population (n = 508) 
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DISCUSSION 
 Carcinoma of the breast is the commonest malignancy in Sudanese females,   
accounting for (34.5%) of all cancers (A/Salam 2003). The incidence of female 
breast cancer in Sudan is among the highest in countries south of the Sahara.(16)  
Invasive lobular carcinoma develops from the acinar epithelium of the 
mammary gland and frequently invades the normal tissue without provoking 
the abundant desmoplastic response that unusually accompanies invasive 
ductal carcinoma.(6) Invasive lobular carcinoma is a form of invasive breast 
cancer that has distinctive pathologic characteristics. The classical tumour is 
diffusely infiltrative and is composed of small, round, regular cells that form 
single lines throughout a desmoplastic stroma.(16,17)  
Invasive lobular carcinoma is the second most common type of breast cancer 
as indicated by many reports.(3,6,7,8,11,13,17) In  the current study the incidence 
rate is 5.9% of all invasive breast carcinomas, is in accordance with the 
incidence rate range of 5- 10% reported in the literature for USA and Europe, 
but less than Japan incidence rate 1-4%.(7) Reviewing the literature, no study 
was conducted in Africa and Sudan reflecting the biological, clinical and 
pathologic features of invasive lobular carcinoma as distinct type of breast 
cancer. 
  
 
This study shows that the incidence is significantly rising, due to an overall 
increase in the incidence of breast cancer, and also due to increased knowledge 
of the different histological subtypes, resulting in accurate diagnosis.(6,7) 
 Several studies showed that patients with invasive lobular carcinoma are on 
average older at presentation than are invasive ductal carcinoma.(6,7,10) 
Consistent with these data, in the present study the median ages at diagnosis 
were   57.5 years (range, 30- 85 years) for patients with ILC and 5.3 (rang, 25-
82 years) for patients with IDC. This older age at the time of diagnosis in those 
with ILC could be due to low proliferative rate or greater difficulties in 
detecting invasive lobular carcinoma. Significantly, in this study invasive 
lobular carcinoma was more common or increasing among postmenopausal 
women.(6,9) 
At the present analyzed data, the tumour histological grade for all invasive 
breast carcinoma is grade 2(38.6%), followed by grade 3(26.6%). Most of the 
invasive lobular carcinoma are grade 2(73.3%), minor portion grade 1 and only 
very few grade 3 tumours. This is to be expected, considering the grading 
method (tubule formation, number of mitoses and nuclear pleomorphism) and 
it correlates well with the findings in other studies.(4, 6,17) Invasive lobular 
carcinoma is mostly of the classical subtype which is morphologically 
consisting of rather small tumour cells, growing in single file without tubule 
  
 
formation. The determining factor for histological malignancy grade in ILC is 
nuclear pleomorphism, as the number of mitosis is limited. Several studies 
showed a correlation between prognosis and histological malignancy grade in 
invasive lobular carcinoma.(8,16,17)   
A Study by (M.-L. Maller Talman etal) included 860 lobular carcinomas found 
a significantly worse prognosis for grade 3 tumours compared to grade 2 
tumours (16). Most of grade 3 tumours are among the other variants of ILC 
such as solid and pleomorphic subtypes whole grade 1 and 2 tumours more 
commonly in the classical subtype.(8,10,11,16) In this study the proportion of ILC 
grade 3 was only 10%, and therefore there is no significant differences in 
prognosis between grade 1 and 2 tumours. 
Histological malignancy grading of ILC is not very common, probably due to a 
weakness of grading method in this type of carcinoma, where the nuclear 
pleomorphism often is the determining factor. However Nottingham studies 
finding quoted by Moller Talman et al.,(16) show that the grading method is a 
powerful prognostic indicator. 
Relating the age distribution with tumour histological grade in ILC, it was 
found that a patient in age range is 40-49 years and few more than 70 years.  In 
the current study it was found that tumour histological grade 2 is more 
  
 
common in postmenopausal age (65%), but this not significantly related to 
prognosis of ILC.  
The incidence of lymph node metastasis with invasive lobular carcinoma 
tended to lower to (40%) in this study. This is may be due the uniform 
appearance of bland tumour cells that lack cellular atypia and often have a low 
mitotic rate making the lobular carcinoma cells more difficult to detect in 
metastatic lymph node. Reports indicated that the proportion of lymph node 
metastasis of ILC occur at the same rate in comparison to other types of 
invasive cancer.(6,7,15)  
In this study the percentage of lymph node metastasis tended to be slightly 
lower in invasive lobular carcinoma as well as in the all invasive breast 
cancers. 
Invasive lobular carcinoma predominantly is hormone receptors positive 
regardless of subtypes.(16) Few small and scattered studies have addressed the 
biologic features of ILC, indicating that lobular carcinomas are significantly 
more likely to steroid positive than other invasive cancer of the breast.(6,7,16) 
This study found that 70% of tumours are ER positive and only 50% PR 
positive. When categorizing the tumour reactivity for hormone receptors, 40% 
are ER/PR positive and only 20% revealed ER/PR negative. Based on the 
current study finding, we can conclude that ER expression is more frequently 
  
 
in invasive lobular carcinoma than in other types of breast cancer. Thus, 
invasive lobular carcinoma is mostly hormone receptor positive. 
In general, the management of the patients in data analyzed is the same for all 
invasive carcinoma, 60% treated by mastectomy. However, this analysis 
suggested that ILC was treated by mastectomy (46.7%) slightly less frequently 
than other invasive carcinomas. In practice, the histologic type appears to play 
a role in the choice of surgical procedure.(6)  
Although this tendency to favor mastectomy may be related to factors specific 
to patients and /or surgeon, the choice of these procedures is also influenced by 
pathologic findings. Indeed, the diminished fibrotic reaction present in ILC 
makes it difficult for pathologist and surgeons to determine the gross extent of 
the disease during surgery, and to achieve tumour-free margins after a limited 
excision.(6,7,16)  
With respect to the systemic therapy, because lobular carcinomas are more 
frequently steroid receptor positive tumours, as expected a greater proportion 
of ILC patients received adjuvant endocrine therapy.(6,7,16) 
 
 
 
 
  
 
CONCLUSION  
 
• The most common specific type of invasive breast carcinoma next to 
invasive ductal carcinoma is invasive lobular carcinoma. 
• The incidence rate of invasive lobular carcinoma is increasing as well as 
other types of invasive breast carcinomas. 
•  Invasive lobular carcinomas are more likely to occur in older patients or 
postmenopausal age. 
• Most of the invasive lobular carcinomas are grade 2 tumours. 
• The percentage of lymph node metastasis tends to be lower in invasive 
lobular carcinomas as well as in other invasive breast cancer. 
• Invasive lobular carcinomas are more frequently hormone receptors 
positive, with increased incidence of receptor reaction to histological grade 
2 tumours.  
 
 
                          
 
 
 
  
 
RECOMMENDATIONS 
  
• Further in-depth studies are highly recommended to address the biological, 
clinical and pathological characteristics of invasive lobular carcinoma and 
other special subtype of breast cancers, to include the following: 
 1- Clinical and epidemiological factors for ILC. 
2- Histological variants of Invasive lobular Carcinoma. 
3- Ductal and lobular insitu carcinoma. 
4- Prognostic factors of invasive lobular carcinoma. 
5- Full microscopic review for breast cancers. 
• This study was challenged by the rarity of invasive lobular breast 
carcinoma, and other limitations, such as missing of some clinical 
information in reported files, no previous studies or reports regarding 
ILC and the data were collected in one center which might not give a 
full account of the disease. Therefore, we recommended prospective 
studies and records improvement. 
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ANNEXES 
Invasive lobular Carcinoma of the breast 
(Working sheet) 
Lab NO: ---------------------------------------------- Date: --------------------------- 
Patient Name: -----------------------------------------Age: --------------------------- 
Specimen Type:   Excision {    }   Mastectomy {    }   other (specify) -------- 
Clinical Information: 
1- Clinical presentation:----------------------------------------------------------- 
2- Primary/recurrent--------------------------------------------------------------- 
3- Past surgery:--------------------------------------------------------------------- 
4- Mammography finding--------------------------------------------------------- 
Gross findings (specific for ILC): 
--------------------------------------------------------------------------------- 
--------------------------------------------------------------------------------- 
----------------------------------------------------------------------------------- 
-------------------------------------------------------------------------------- 
Microscopic findings (specific for ILC): 
-------------------------------------------------------------------------------------------- 
-----------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------- 
------------------------------------------------------------------------------------------- 
 
 
  
 
Histological type: 
1- Invasive Ductal Carcinoma, IDC                         {             } 
2- Invasive lobular carcinoma , ILC (Classic type) {              } 
3- Invasive lobular carcinoma  variants                    {             } 
4- Other Invasive breast carcinoma                          {             } 
Histological grade:  
1- Grade 1:  
  Tubules formation  {         }                Nuclear pleomorphism {                   }                        
mitotic count/10HPF {        } 
 2-Grade 2:      
Tubule formation {             }                Nuclear Pleomorphism {                   }   
Mitotic count/10HPF {       } 
3-Grade3:  
Tubules formation {           }              Nuclear pelomorphism {                      } 
Mitotic Count/10HPF {       } 
4- Grade cannot be determined 
Lymph node involvement:      Involved {     }      not involved {     } 
ER/PR Status:                           Positive {     }       Negative {          } 
 
 
 
 
 
 
 
 
 
  
 
     ILC Working Sheet     
Age 
Specimen Type Histological Types 
Histological 
Grade  
Lymph Nodes 
Involvment ER/RE Status 
Biopsy M.Tomy IDC ILC ILC(V) Others  1 2 3 N D Involved 
Not 
Involved R NR Result 
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